Compare EVC & ALDX Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
Current Price
| Metric | EVC | ALDX |
|---|---|---|
| Founded | 1996 | 2004 |
| Country | United States | United States |
| Employees | N/A | N/A |
| Industry | Broadcasting | Biotechnology: Pharmaceutical Preparations |
| Sector | Industrials | Health Care |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 273.8M | 317.7M |
| IPO Year | 2000 | 2014 |
| Metric | EVC | ALDX |
|---|---|---|
| Price | $2.99 | $4.14 |
| Analyst Decision | | Strong Buy |
| Analyst Count | 0 | 2 |
| Target Price | N/A | ★ $9.50 |
| AVG Volume (30 Days) | 349.6K | ★ 1.0M |
| Earning Date | 06-10-2026 | 01-01-0001 |
| Dividend Yield | ★ 6.60% | N/A |
| EPS Growth | ★ 47.59 | 40.43 |
| EPS | N/A | ★ N/A |
| Revenue | ★ $536,034,000.00 | N/A |
| Revenue This Year | N/A | N/A |
| Revenue Next Year | N/A | $123.43 |
| P/E Ratio | N/A | ★ N/A |
| Revenue Growth | N/A | N/A |
| 52 Week Low | $1.76 | $1.18 |
| 52 Week High | $3.68 | $6.99 |
| Indicator | EVC | ALDX |
|---|---|---|
| Relative Strength Index (RSI) | 47.20 | 34.77 |
| Support Level | $2.85 | $2.60 |
| Resistance Level | $3.17 | $5.70 |
| Average True Range (ATR) | 0.16 | 0.43 |
| MACD | -0.01 | -0.10 |
| Stochastic Oscillator | 13.66 | 6.36 |
Entravision Communications Corp owns and operates Spanish language television and radio stations in the United States. The Company also owns and operates a smaller group of television stations that broadcast English language programming and has operations that provide programmatic advertising technology and services. The Company has organized its operations into two reportable segments. Its media segment includes its television, radio, and digital marketing operations. Its advertising and technology services segment provides programmatic advertising and technology services. The company generates the majority of its revenue from the Media segment. Geographically, the company generates the majority of its revenue from the United States.
Aldeyra Therapeutics Inc is a biotechnology company engaged in developing and commercializing next-generation medicines to improve the lives of patients with immune-mediated and metabolic diseases. The company's product candidate, Reproxalap, is a treatment in late-stage development for dry eye disease and allergic conjunctivitis. In addition, it also has additional product candidates in development for proliferative vitreoretinopathy, primary vitreoretinal lymphoma and other retinal diseases, autoimmune disease, and cancer. Company products includes ADX248, ADX743, ADX631, ADX246, ADX629, ADX2191.